OncoMatch/Clinical Trials/NCT05790213
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
Is NCT05790213 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Androgen Deprivation Therapy (ADT) for prostate cancer.
Treatment: Androgen Deprivation Therapy (ADT) — The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage ≤ CLINICAL STAGE T2C (clinical)
Excluded: Stage III, NODAL, IV
Grade: GG2GG3 (Grade Group)
a. Favorable intermediate-risk PCa: i. ≤ clinical stage T2c, GG2, and PSA ≤ 10 ng/mL, and <50% positive biopsy cores with PCa b. Unfavorable intermediate-risk PCa: i. ≤ clinical stageT2c, GG2, and PSA 10-20 ng/mL, or ≥50% positive biopsy cores with PCa, or ii. ≤ clinical stage T2c, GG3, and PSA < 20 ng/mL
Performance status
ECOG OR KARNOFSKY 0–2
ECOG performance status ≤ 2 or Karnofsky Performance Status Scale Score ≥ 60%
Prior therapy
Cannot have received: biologic
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: chemotherapy
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: hormone therapy
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: radiotherapy
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: surgery
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: pelvic radiation
Exception: for a separate hematologic or visceral malignancy within 6-months of enrollment
Subjects may not have had undergone pelvic radiation, chemotherapy or immunotherapy treatment for a separate hematologic or visceral malignancy within 6-months of enrollment in the present study.
Cannot have received: chemotherapy
Exception: for a separate hematologic or visceral malignancy within 6-months of enrollment
Subjects may not have had undergone pelvic radiation, chemotherapy or immunotherapy treatment for a separate hematologic or visceral malignancy within 6-months of enrollment in the present study.
Cannot have received: immunotherapy
Exception: for a separate hematologic or visceral malignancy within 6-months of enrollment
Subjects may not have had undergone pelvic radiation, chemotherapy or immunotherapy treatment for a separate hematologic or visceral malignancy within 6-months of enrollment in the present study.
Lab requirements
Blood counts
Hemoglobin ≥ 10 g/dL; Leukocytes ≥ 3,000/mcL; Absolute neutrophil count ≥ 1,500/mcL; Platelets ≥ 100,000/mcL
Kidney function
Creatinine < 1.5 institutional ULN OR Calculated or measured creatinine clearance > 50 mL/min/1.73 m2; eGFR >30 mL/min using the MDRD formula; Serum potassium ≥3.5 mmol/L
Liver function
Total bilirubin ≤ 1.5 x institutional ULN; AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN; Serum albumin ≥3.0 g/dL
Subjects must have adequate organ and marrow function as defined below: Hemoglobin ≥ 10 g/dL Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN Creatinine < 1.5 institutional ULN OR Calculated or measured creatinine clearance > 50 mL/min/1.73 m2 eGFR >30 mL/min using the MDRD (modification of diet and renal disease) formula Serum albumin ≥3.0 g/dL Serum potassium ≥3.5 mmol/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UChicago Medicine Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify